Global Heart Failure Burden Climbs With Age and Geography
Heart failure affected an estimated 56.0 million people worldwide in 2023, with the burden rising steadily across age groups and varying sharply by geography and cause. The global estimate, drawn from Global Burden of Diseases, Injuries, and Risk Factors Study methods across 204 countries and territories, captures a condition that is now deeply shaped not only by aging populations, but also by the cardiovascular risk profile of each region.
The prevalence curve moved upward with advancing age in every location. In older adults, ischemic heart disease and hypertensive heart disease remained the dominant causes, a pattern that fits the cumulative vascular injury of longstanding atherosclerosis, afterload stress, and ventricular remodeling. In practical terms, the heart failure epidemic is not a single disease process. It is a collection of end-stage pathways that emerge from different upstream insults, and the dominant insult changes by setting, age, and access to prevention.
One sentence captures the scale of the issue: heart failure is now a global chronic disease burden rather than a problem confined to high-income health systems.
Etiology Patterns Shift Across Regions, Ages, and Exposures
The distribution of underlying etiologies was far from uniform. Congenital heart anomalies and rheumatic heart disease were important causes in children and young adults, reflecting the persistent footprint of early-life structural disease and post-streptococcal valvular injury. In middle adulthood, the proportion of heart failure attributable to alcohol use peaked, pointing to a preventable cardiomyopathic pathway driven by toxic myocardial injury, arrhythmogenic risk, and progressive contractile dysfunction.
Location-specific estimates exposed marked clustering of certain etiologies. Rheumatic heart disease accounted for a higher burden in south Asia, east Asia, Oceania, southeast Asia, central sub-Saharan Africa, eastern sub-Saharan Africa, southern sub-Saharan Africa, and western sub-Saharan Africa. Alcohol-related heart failure was more prominent in eastern Europe, Australasia, the Caribbean, and central Europe. Chagas disease contributed substantially in southern, Andean, tropical, and central Latin America.
Those regional differences matter because prevention is not generic. A health system facing a high rheumatic burden needs better early detection of streptococcal infection, secondary prophylaxis, and valve-disease care. A system where alcohol use drives a large share of cases needs stronger substance-use prevention and treatment pathways. In places where hypertensive and ischemic disease dominate, the most effective intervention may be simpler on paper but difficult in execution: sustained control of blood pressure, tobacco exposure, and cardiometabolic risk.
Prevention Targets Sit Upstream of Most Heart Failure Etiologies
The burden of heart failure continues to expand because the conditions that lead to it remain common, chronic, and incompletely controlled. Elevated blood pressure, excessive alcohol consumption, and tobacco use are among the modifiable exposures most tightly linked to downstream myocardial damage. Reducing those risks would not eliminate every case, but it would intercept many of the pathways that culminate in ventricular dysfunction, congestion, reduced exercise tolerance, and repeated hospital care.
This study’s value lies in its ability to separate broad prevalence from local cause structure. A national estimate alone can hide the fact that two countries with the same overall heart failure burden may need entirely different prevention strategies. One may need better ischemic disease control in older adults. Another may need aggressive rheumatic fever prevention in youth and young adults. A third may need stronger surveillance for Chagas cardiomyopathy, or public health action against alcohol-related myocardial injury.
The pathophysiology also explains why the burden continues to accumulate even where acute cardiovascular mortality has improved. More people survive myocardial infarction, valvular disease, and other cardiac insults, but survival does not erase the downstream remodeling that can lead to chronic heart failure. As populations age, the reservoir of individuals living with prior cardiac injury expands, and with it the number of patients who progress into symptomatic disease.
Why These Estimates Matter for Health Systems Planning
Global Burden of Disease methods provide a way to compare disease patterns across countries using a consistent framework, which is especially important when direct surveillance is incomplete or uneven. Here, the estimates extended from 1990 through 2023 and allowed comparisons by age, sex, location, year, and underlying etiology. That structure gives public health leaders something more useful than a single headline number: it identifies where the burden sits, who is most affected, and what is likely driving the cases.
For clinicians and policy makers, the implications are concrete. Heart failure clinics, inpatient services, and outpatient prevention programs should not assume that the same etiologic mix applies everywhere. In some settings, the highest-yield work will center on valvular disease and rheumatic prevention. In others, alcohol harm reduction or tobacco control may carry more weight. Elsewhere, the main battle remains blood pressure control and secondary prevention after ischemic heart disease.
The study also reinforces a harder truth about global cardiovascular health. Heart failure is not simply a late complication of individual disease; it is a visible endpoint of broader failures in prevention, screening, and chronic disease management. Aging will push case counts higher, but the distribution of those cases will continue to depend on which upstream risks health systems manage well and which they leave unchecked.
No single intervention will flatten the global burden. The remaining task is to match prevention to etiology and geography, because the data show that heart failure does not follow the same script in every population.